Evotec (EVT) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for August 7, 2025, at the principal office in Boston, MA, for five Eaton Vance closed-end funds.
Main agenda is the election of Class I Trustees for each fund, with all nominees currently serving and recommended for re-election.
Shareholders are encouraged to vote by proxy, with detailed instructions provided for both record holders and those holding shares through intermediaries.
Proxy materials, including the notice, statement, and reports, are available online for shareholder review.
Voting matters and shareholder proposals
Election of Trustees is the sole proposal, with specific nominees listed for each fund and voting classes.
Shareholders may also act on any other matters properly brought before the meeting.
Shareholder proposals for the 2026 meeting must be received by February 23, 2026, for inclusion under Rule 14a-8.
Board of directors and corporate governance
Each fund's board consists of ten noninterested Trustees, divided into three classes with staggered three-year terms.
Trustees bring diverse backgrounds in investment management, finance, and governance, with detailed biographies and directorships disclosed.
Board committees include Audit, Contract Review, Portfolio Management, Compliance, Closed-End Fund, and Governance, each with defined responsibilities.
Board and committee meetings are held regularly, with high attendance and active participation.
Board considers diversity in skills and backgrounds when evaluating candidates, with six of ten Trustees contributing gender and/or racial diversity.
Latest events from Evotec
- Transformation targets €75M savings by 2027 and >€1B revenues with 20%+ EBITDA margin by 2028.EVT
Status update10 Mar 2026 - Strong JEB growth, asset-light pivot, and robust pipeline drive mid-term value creation.EVT
Company presentation10 Mar 2026 - Revenue up 2%, but losses deepen and restructuring accelerates for 2025 recovery.EVT
Q2 20241 Feb 2026 - Biologics growth and cost savings offset R&D softness, supporting 2024 guidance.EVT
Q3 202416 Jan 2026 - Strong Q4, cost savings, and biologics growth set up 5–10% revenue rise in 2025.EVT
Q4 20242 Dec 2025 - Shareholders will vote on electing Class III Trustees and review key governance and audit matters.EVT
Proxy Filing2 Dec 2025 - JEB grew 16% as group revenues fell 5%, with a strategic reset and €300m asset sale planned.EVT
Q2 202523 Nov 2025 - Q1 revenue fell 4% but Biologics grew 10–11%; guidance and cost savings remain on track.EVT
Q1 202519 Nov 2025 - JEB growth and a major Sandoz deal offset D&PD softness, supporting 2025 guidance.EVT
Q3 202513 Nov 2025